Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company